Tradestie Institutional Equity Comparison Engine

LCTX vs CBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LCTX Overall Edge

LCTX Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin, Options & Structure while CBIO counters with relative strength in Momentum & Technical. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus CBIO at N/M Forward P/E and -1228.4% operating margin (+0.0% YoY). In options structure, LCTX sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against CBIO sits in BREAKDOWN (98th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
LCTX 30.7x vs CBIO N/M Fwd P/E
Growth & Margin Winner LCTX
Op Margin -280.3% vs -1228.4% ยท YoY -61.0% vs +0.0%
Momentum & Technical Winner CBIO
1Y -54.9% vs -0.2% ยท 52W Pos 0% vs 23%
Options & Structure Winner LCTX
BREAKDOWN (<1st %ile IV) vs BREAKDOWN (98th %ile IV)
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
1M Return -21.63%
1Y Return -54.86%
Forward P/E 30.7x
Unified AI Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0
CBIO NASDAQ
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.00
+0.7% 1D
Market Cap $539.5M
1M Return -1.07%
1Y Return -0.23%
Forward P/E N/M
Unified AI Score
49.2 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LCTX -54.86% CBIO -0.23% Spread: +54.63 pp (CBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LCTX Revenue CBIO Revenue LCTX Op. Margin CBIO Op. Margin Margin Edge
FY2018 $0M N/A -837.9% N/A LCTX
FY2019 $0M N/A -1106.0% N/A LCTX
FY2020 $0M $10M -1448.4% -506.8% CBIO
FY2021 $0M $0M -1133.6% -5470.7% LCTX
FY2022 $10M $0M -153.2% -63204.4% LCTX
FY2023 $10M $0M -276.5% -392752.9% LCTX
FY2024 $10M N/A -226.1% N/A LCTX
FY2025 $10M $10M -251.6% -1407.5% LCTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LCTX (6) vs CBIO (4)
Institutional Metric LCTX CBIO Criterion Row Winner
Market Capitalization Scale $207.4M $539.5M Larger Scale CBIO
Trailing P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Forward P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY) Growth -61.0% +0.0% Higher Growth CBIO
Operating Margin (TTM) Profitability -280.3% -1228.4% Higher Margin LCTX
Net Profit Margin Profitability 16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency 4.3% -160.8% Higher ROE LCTX
52-Week Range Position Momentum 0% ($1โ€“$2) 23% ($9โ€“$27) Stronger Trend CBIO
Beta / 30D Volatility Risk Regime 1.39ฮฒ ยท 79% Vol 1.18ฮฒ ยท 60% Vol Lower Realized Risk CBIO
Unified Institutional Score Composite Signal 54.9 / 100 (HOLD) 49.2 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LCTX vs CBIO Buy Guide
LCTX BREAKDOWN
7d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CBIO BREAKDOWN
148d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 98th %ile
IV Regime Extreme (>80th %ile)
Live CBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LCTX nor CBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.